Brady Cummins

Brady Cummins is a partner in Goodwin’s Antitrust and Competition practice. He advises clients on all aspects of antitrust issues related to mergers and acquisitions including US and international antitrust filing assessments, antitrust risk assessments, risk-shifting negotiations and agreements, and FTC and DOJ investigations. Brady has advocated on behalf of clients across a broad range of industries before the FTC, DOJ, and state enforcers during all aspects of merger investigations as well as conduct and cartel investigations.

Prior to joining Goodwin, Brady practiced at Latham & Watkins LLP. Prior to private practice, Brady was a law clerk in the Mergers IV Division of the FTC Bureau of Competition.

Brady’s representative experience includes:

• Vesalius Therapeutics in its multi-target strategic alliance with GSK for $80 million upfront and up to $570 million in potential milestones and tiered royalties
• Zuora in its $1.7 billion proposed acquisition by Silver Lake and GIC
• Markforged in its $115 million proposed acquisition by Nano Dimension
• Renesas Electronics Corporation in its $345 million acquisition of Transphorm, Inc.
• Deciphera Pharmaceuticals, Inc. in its $2.4 billion sale to ONO Pharmaceutical Co., Ltd.
• Thoma Bravo and its portfolio company Flexera in the acquisition of IT asset management firm Snow Software
• Tata Communications Limited in its $100 million acquisition of Kaleyra, Inc.
• Renesas Electronics Corporation in its $249 million acquisition of Sequans Communications S.A.
• Mimecast Limited in its acquisition by Permira for approximately $5.8 billion
• Citrix Systems in its acquisition by affiliates of Vista Equity Partners Elliott Investment Management L.P.for $16.5 billion
• Deliverr in its sale to Shopify for $2.1 billion
• Pixomondo in its acquisition by Sony Pictures Entertainment
• Poshmark in its acquisition by Naver Corporation for approximately $1.6 billion
• Checkr in its acquisition of GoodHire
• Bio Products Laboratory (BPL) in its combination with Kedrion Biopharma and acquisition by funds advised by Permira Capital Partners
• Lucid Holdings in its acquisition by Cint Group AB for $1.1 billion
• DaVita Medical Group in its acquisition by UnitedHealthcare*
• Agrium in its merger with PotashCorp*
• Nissan in its acquisition of a controlling stake in Mitsubishi Motors*
• Orbitz in its acquisition by Expedia*

*Denotes experience prior to joining Goodwin.

Brady was recognized as a One to Watch in Antitrust Law by The Best Lawyers in America 2023-2025.

Brady is a contributor to Goodwin’s Antitrust Trends in Technology, Life Sciences, and Healthcare series, which provides quarterly analysis and commentary on antitrust developments. His other recent publications include:

• Co-author, “United States: DOJ and FTC to Shift Focus to AI as Stringent Merger Enforcement Chills Tech Deals,” Global Competition Review’s Digital Markets Guide, October 2, 2024
• Co-Author, “Digital Markets Guide: US Scepticism of Tech Transactions Sparks a Step-Up in Merger Enforcement,” The Global Competition Review, March 11, 2024
• Co-Author, “White House Unveils Landmark Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence,” Goodwin Client Alert, October 31, 2023
• Co-Author, “US Antitrust Agencies Release Revised Draft Merger Guidelines,” Goodwin Client Alert, July 20, 2023
• Co-Author, “United States: FTC Looks Set to Open up New Enforcement Front,” Global Competition Review, October 21, 2022
• Co-Author, “Recent FTC Enforcement Action Signifies Increased Scrutiny of Private Equity Acquisitions and Imposition of More Onerous Settlement Terms,” Goodwin Client Alert, June 17, 2022
• Co-Author, “Tools of Reason: Truncation Through Judicial Experience and Economic Learning,” Antitrust Magazine, 2014